Exagen XGN 深 滬
已收盤 08-07 16:00:00 美东时间
6.87
+0.280
+4.25%
華盛通- 最 高6.94
- 今 開6.68
- 成交量 43.19万股
- 最 低 6.48
- 昨 收 6.59
- 總市值 1.66亿
- 52周最高 12.23
- 市盈率 靜 --
- 換手率 1.78%
- 52周最低 2.59
- 委 比 44.40%
- 總股本 2422.53万
- 歷史最高 29.858
- 量 比 0.46
- 振 幅 6.98%
- 歷史最低 1.3003
- 每 手 1
- 風險率 2.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
BTIG Maintains Buy on Exagen, Raises Price Target to $9
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.
08-05 20:08
美股牛股 | 绩优股齐升！Palantir大涨逾29%，Q2营收强劲增长并上调全年指引；Wayfair飙升30%，Corvex涨逾27%
绩优股齐升！Palantir大涨逾29%，Q2营收暴增93%并上调全年指引；Wayfair飙升30%，Q2业绩全面超预期；Corvex涨逾27%，斩获AI巨头Blackwell供应协议>>
08-05 19:24
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
08-04 22:21
北美市场早间简报：科技股反弹持续，股指期货走高
Suncor Energy 第二季度财报 经济指标（美东时间）： 08：30 6月国际商品贸易 09：30 7月加拿大制造业PMI 值得关注...
08-04 20:20
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est
Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
08-04 20:01
中东战火催化出油气巨头强劲业绩，埃克森美孚利润创俄乌冲突以来新高
尽管原油价格飙升，燃油生产利润率不断扩大，但随着美伊冲突进入第六个月，埃克森美孚控股公司仍未能达到盈利预期。该公司总利润为 147 亿美元，是自 2022 年俄罗斯入侵乌克兰扰乱全球市场以来最高的，但经调整后的第二季度收益比平均预期低 2 美分。
07-31 20:50
Exagen Inc. to Participate in Upcoming Investor Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune diagnostics, announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The event will feature a Fireside Chat at 8:30am ET, available live and archived on Exagen’s Investor Relations website. Exagen, based in California, focuses on improving autoimmune disease management through innovative testing solutions like AVISE® CTD, aidi...
07-28 13:00
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
Exagen to Announce Second Quarter Financial Results on August 4, 2026
Exagen Inc. will release its Q2 2026 financial results on August 4, 2026, before market open. John Aballi and Jeff Black will host a conference call at 8:30 a.m. ET to discuss the results. The call and webcast will be available via investors.exagen.com. A replay will be accessible until August 18, 2026. Exagen is a leader in autoimmune diagnostics, focusing on improving outcomes for patients with chronic autoimmune conditions through innovative t...
07-21 13:00
